Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by HENRY MARK KUERER and SAVITRI KRISHNAMURTHY.
HENRY MARK KUERER
Connection Strength
5.474
SAVITRI KRISHNAMURTHY
  1. Comment on 'Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques'. Br J Cancer. 2016 05 10; 114(10):e3.
    View in: PubMed
    Score: 0.567
  2. Nipple aspirate fluid cytology in breast carcinoma. Cancer. 2003 Apr 25; 99(2):97-104.
    View in: PubMed
    Score: 0.230
  3. Eliminating Breast Surgery for Invasive Cancer with Exceptional Response to Neoadjuvant Systemic Therapy: Prospective Multicenter Clinical Trial Planned Initial Feasibility Endpoint. J Am Coll Surg. 2023 07 01; 237(1):101-108.
    View in: PubMed
    Score: 0.228
  4. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2022 Dec; 23(12):1517-1524.
    View in: PubMed
    Score: 0.223
  5. Foam cells in nipple aspiration fluid. Cytopathology. 2002 Feb; 13(1):64.
    View in: PubMed
    Score: 0.212
  6. Accuracy of Post-Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer. JAMA Surg. 2020 12 01; 155(12):e204103.
    View in: PubMed
    Score: 0.195
  7. Patient Selection for Clinical Trials Eliminating Surgery for HER2-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy. Ann Surg Oncol. 2019 Oct; 26(10):3071-3079.
    View in: PubMed
    Score: 0.178
  8. Ductal Carcinoma In Situ and Margins <2?mm: Contemporary Outcomes With Breast Conservation. Ann Surg. 2019 01; 269(1):150-157.
    View in: PubMed
    Score: 0.171
  9. Optimal Selection of Breast Cancer Patients for Elimination of Surgery Following Neoadjuvant Systemic Therapy. Ann Surg. 2018 12; 268(6):e61-e62.
    View in: PubMed
    Score: 0.170
  10. A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. Ann Surg. 2018 05; 267(5):946-951.
    View in: PubMed
    Score: 0.163
  11. Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancer. Br J Surg. 2018 04; 105(5):535-543.
    View in: PubMed
    Score: 0.161
  12. DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes. J Cancer. 2017; 8(14):2653-2662.
    View in: PubMed
    Score: 0.156
  13. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery. JAMA Surg. 2017 07 01; 152(7):665-670.
    View in: PubMed
    Score: 0.154
  14. Paradigm Shifts in Breast Care Delivery: Impact of Imaging in a Multidisciplinary Environment. AJR Am J Roentgenol. 2017 Feb; 208(2):248-255.
    View in: PubMed
    Score: 0.148
  15. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. J Clin Oncol. 2016 Apr 01; 34(10):1072-8.
    View in: PubMed
    Score: 0.139
  16. Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: a prospective feasibility trial. JAMA Surg. 2015 Feb; 150(2):137-43.
    View in: PubMed
    Score: 0.130
  17. Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted? Ann Surg Oncol. 2013 Dec; 20(13):4103-12.
    View in: PubMed
    Score: 0.118
  18. Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer. Cancer Med. 2013 Apr; 2(2):226-33.
    View in: PubMed
    Score: 0.114
  19. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol. 2012 Jul; 13(7):688-95.
    View in: PubMed
    Score: 0.108
  20. Multidisciplinary considerations in the management of high-risk breast lesions. AJR Am J Roentgenol. 2012 Feb; 198(2):W132-40.
    View in: PubMed
    Score: 0.106
  21. Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy. Ann Surg Oncol. 2010 Nov; 17(11):2899-908.
    View in: PubMed
    Score: 0.094
  22. A prospective study comparing touch imprint cytology, frozen section analysis, and rapid cytokeratin immunostain for intraoperative evaluation of axillary sentinel lymph nodes in breast cancer. Cancer. 2009 Apr 01; 115(7):1555-62.
    View in: PubMed
    Score: 0.087
  23. Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol. 2009 Jan 10; 27(2):279-88.
    View in: PubMed
    Score: 0.085
  24. Breast cancer in the asian Indian population of the United States: a call for screening and education. Breast J. 2008 Jul-Aug; 14(4):402-3.
    View in: PubMed
    Score: 0.083
  25. Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein. BMC Cancer. 2006 Mar 16; 6:68.
    View in: PubMed
    Score: 0.070
  26. Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. Breast Cancer Res Treat. 2005 Jan; 89(2):149-57.
    View in: PubMed
    Score: 0.065
  27. Association between ductal fluid proteomic expression profiles and the presence of lymph node metastases in women with breast cancer. Surgery. 2004 Nov; 136(5):1061-9.
    View in: PubMed
    Score: 0.064
  28. Feasibility and utility of using chromosomal aneusomy to further define the cytologic categories in nipple aspirate fluid specimens: a preliminary study. Cancer. 2004 Oct 25; 102(5):322-7.
    View in: PubMed
    Score: 0.064
  29. Prospective evaluation of a novel approach for the use of a quantitative galactose oxidase-Schiff reaction in ductal fluid samples from women with breast carcinoma. Cancer. 2004 Jun 15; 100(12):2549-54.
    View in: PubMed
    Score: 0.062
  30. Patient Interest in Exploring Nonsurgical Treatment Approaches for Early-Stage Breast Cancer: A Qualitative Study. Int J Radiat Oncol Biol Phys. 2024 Feb 01; 118(2):443-454.
    View in: PubMed
    Score: 0.059
  31. Patient-Reported Outcomes of Omission of Breast Surgery Following Neoadjuvant Systemic Therapy: A Nonrandomized Clinical Trial. JAMA Netw Open. 2023 09 05; 6(9):e2333933.
    View in: PubMed
    Score: 0.059
  32. High and differential expression of HER-2/neu extracellular domain in bilateral ductal fluids from women with unilateral invasive breast cancer. Clin Cancer Res. 2003 Feb; 9(2):601-5.
    View in: PubMed
    Score: 0.057
  33. Role of ultrasound-guided fine-needle aspiration of indeterminate and suspicious axillary lymph nodes in the initial staging of breast carcinoma. Cancer. 2002 Sep 01; 95(5):982-8.
    View in: PubMed
    Score: 0.055
  34. Prospective Registry Trial Assessing the Use of Magnetic Seeds to Locate Clipped Nodes After Neoadjuvant Chemotherapy for Breast Cancer Patients. Ann Surg Oncol. 2021 Aug; 28(8):4277-4283.
    View in: PubMed
    Score: 0.049
  35. Feasibility of fine-needle aspiration for assessing responses to chemotherapy in metastatic nodes marked with clips in breast cancer: A prospective registry study. Cancer. 2019 02 01; 125(3):365-373.
    View in: PubMed
    Score: 0.042
  36. Biopsy Feasibility Trial for Breast Cancer Pathologic Complete Response Detection after Neoadjuvant Chemotherapy: Imaging Assessment and Correlation Endpoints. Ann Surg Oncol. 2018 Jul; 25(7):1953-1960.
    View in: PubMed
    Score: 0.041
  37. Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast?Cancer. Clin Breast Cancer. 2018 02; 18(1):e73-e77.
    View in: PubMed
    Score: 0.039
  38. Radiologic Mapping for Targeted Axillary Dissection: Needle Biopsy to Excision. AJR Am J Roentgenol. 2016 Dec; 207(6):1372-1379.
    View in: PubMed
    Score: 0.037
  39. Confocal fluorescence microscopy to evaluate changes in adipocytes in the tumor microenvironment associated with invasive ductal carcinoma and ductal carcinoma in situ. Int J Cancer. 2016 09 01; 139(5):1140-9.
    View in: PubMed
    Score: 0.036
  40. Microcalcifications in 1657 Patients with Pure Ductal Carcinoma in Situ of the Breast: Correlation with Clinical, Histopathologic, Biologic Features, and Local Recurrence. Ann Surg Oncol. 2016 Feb; 23(2):482-9.
    View in: PubMed
    Score: 0.034
  41. Circulating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer. J Natl Cancer Inst. 2015 Nov; 107(11).
    View in: PubMed
    Score: 0.034
  42. Micro-anatomical quantitative optical imaging: toward automated assessment of breast tissues. Breast Cancer Res. 2015 Aug 20; 17:105.
    View in: PubMed
    Score: 0.034
  43. Is Sentinel Lymph Node Dissection Warranted for Patients with a Diagnosis of Ductal Carcinoma In Situ? Ann Surg Oncol. 2015 Dec; 22(13):4270-9.
    View in: PubMed
    Score: 0.033
  44. Correlation between sonographic findings and clinicopathologic and biologic features of pure ductal carcinoma in situ in 691 patients. AJR Am J Roentgenol. 2015 Apr; 204(4):878-88.
    View in: PubMed
    Score: 0.033
  45. Circulating tumor cells in non-metastatic triple-negative breast cancer. Breast Cancer Res Treat. 2014 Sep; 147(2):325-33.
    View in: PubMed
    Score: 0.032
  46. Predicting the extent of nodal disease in early-stage breast cancer. Ann Surg Oncol. 2014 Oct; 21(11):3440-7.
    View in: PubMed
    Score: 0.031
  47. Implementation of the american college of surgeons oncology group z1071 trial data in clinical practice: is there a way forward for sentinel lymph node dissection in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy? Ann Surg Oncol. 2014 Aug; 21(8):2468-73.
    View in: PubMed
    Score: 0.031
  48. Feasibility of confocal fluorescence microscopy for real-time evaluation of neoplasia in fresh human breast tissue. J Biomed Opt. 2013 Oct; 18(10):106016.
    View in: PubMed
    Score: 0.030
  49. Clinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status. Breast Cancer Res Treat. 2013 Jun; 139(3):639-47.
    View in: PubMed
    Score: 0.029
  50. Invasive lobular carcinoma predicts micrometastasis in breast cancer. J Surg Res. 2012 Sep; 177(1):93-6.
    View in: PubMed
    Score: 0.027
  51. Epstein-Barr virus is seldom found in mammary epithelium of breast cancer tissue using in situ molecular methods. Breast Cancer Res Treat. 2012 Feb; 132(1):267-74.
    View in: PubMed
    Score: 0.026
  52. Prospective evaluation of the nipple-areola complex sparing mastectomy for risk reduction and for early-stage breast cancer. Ann Surg Oncol. 2012 Apr; 19(4):1137-44.
    View in: PubMed
    Score: 0.026
  53. Limited evidence of human papillomavirus in [corrected] breast tissue using molecular in situ methods. Cancer. 2012 Mar 01; 118(5):1212-20.
    View in: PubMed
    Score: 0.026
  54. Disseminated tumor cells predict survival after neoadjuvant therapy in primary breast cancer. Cancer. 2012 Jan 15; 118(2):342-8.
    View in: PubMed
    Score: 0.025
  55. Disseminated tumor cells in biologic subtypes of stage I-III breast cancer patients. Ann Surg Oncol. 2010 Dec; 17(12):3252-8.
    View in: PubMed
    Score: 0.024
  56. A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients. Cancer. 2010 Jun 01; 116(11):2543-8.
    View in: PubMed
    Score: 0.024
  57. Role of primary tumor characteristics in predicting positive sentinel lymph nodes in patients with ductal carcinoma in situ or microinvasive breast cancer. Am J Surg. 2008 Jul; 196(1):81-7.
    View in: PubMed
    Score: 0.020
  58. Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastases after a positive sentinel node biopsy. Ann Surg Oncol. 2006 Mar; 13(3):310-20.
    View in: PubMed
    Score: 0.017
  59. Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid. Clin Cancer Res. 2005 Dec 01; 11(23):8312-20.
    View in: PubMed
    Score: 0.017
  60. Intramammary lymph node metastases are an independent predictor of poor outcome in patients with breast carcinoma. Cancer. 2004 Sep 15; 101(6):1330-7.
    View in: PubMed
    Score: 0.016
  61. Feasibility of breast-conserving surgery for patients with breast carcinoma associated with nipple discharge. Cancer. 2004 Aug 01; 101(3):508-17.
    View in: PubMed
    Score: 0.016
  62. Impact of clinicopathological factors on sensitivity of axillary ultrasonography in the detection of axillary nodal metastases in patients with breast cancer. Ann Surg Oncol. 2003 Nov; 10(9):1025-30.
    View in: PubMed
    Score: 0.015
  63. Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer. Ann Surg Oncol. 2003 Apr; 10(3):248-54.
    View in: PubMed
    Score: 0.014
  64. Histologic localization of sentinel lymph node metastases in breast cancer. Am J Surg Pathol. 2003 Mar; 27(3):385-9.
    View in: PubMed
    Score: 0.014
  65. Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy. Cancer. 2003 Feb 15; 97(4):926-33.
    View in: PubMed
    Score: 0.014
  66. Classifying local disease recurrences after breast conservation therapy based on location and histology: new primary tumors have more favorable outcomes than true local disease recurrences. Cancer. 2002 Nov 15; 95(10):2059-67.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.